Curaleaf Holdings (CURLF) Total Non-Current Liabilities (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Total Non-Current Liabilities of $1.3 billion for Q4 2025, up 1.85% year-over-year from $1.3 billion in Q4 2024, and up 1.85% quarter-over-quarter from $1.3 billion in Q4 2024.
Curaleaf Holdings (CURLF) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Curaleaf Holdings' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $1.3 billion for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 1.85% year-over-year to $1.3 billion; the TTM figure through Dec 2025 stood at $1.3 billion (up 1.85% YoY), while the FY2025 annual figure was $1.3 billion, up 1.85% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $1.3 billion, up from $1.3 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $2.0 billion in Q3 2023, with the low at -$6.6 billion in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $1.3 billion (2025), against an average of $640.6 million.
- Peak annual rise in Total Non-Current Liabilities reached 24165.83% in 2022, while the deepest fall reached 715.47% in 2022.
- Curaleaf Holdings' Total Non-Current Liabilities stood at $4.2 million in 2021, then jumped by 24165.83% to $1.0 billion in 2022, then surged by 33.87% to $1.4 billion in 2023, then declined by 4.82% to $1.3 billion in 2024, then climbed by 1.85% to $1.3 billion in 2025.
- Business Quant data shows CURLF's Total Non-Current Liabilities at $1.3 billion in Q4 2025, $1.3 billion in Q4 2024, and $68000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Curaleaf Holdings | 2.51 Bn | 2.42 Bn | 169.91 Mn | 1.48 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.48 Bn |
| Dec 31, 2025 | 1.31 Bn |
| Dec 31, 2024 | 1.29 Bn |
| Sep 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 807,000.00 |
| Dec 31, 2023 | 1.35 Bn |
| Sep 30, 2023 | 2.01 Bn |
| Jun 30, 2023 | 1.90 Bn |
| Dec 31, 2022 | 1.01 Bn |
| Sep 30, 2022 | 1.83 Bn |
| Jun 30, 2022 | 1.73 Bn |
| Mar 31, 2022 | -6.61 Bn |
| Dec 31, 2021 | 4.16 Mn |
| Sep 30, 2021 | 1.39 Bn |
| Jun 30, 2021 | 1.32 Bn |
| Mar 31, 2021 | 1.07 Bn |
| Dec 31, 2020 | 982.82 Mn |
| Sep 30, 2020 | 932.36 Mn |
| Dec 31, 2019 | 300.86 Mn |